NIDDK Central Repository - High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity.

An official website of the United States government

NIDDK Central Repository

Publication Information

DOI

10.1111/liv.12932

PubMed ID

26344576

Public Release Type

Journal

Publication Year

2016

Affiliation

Janssen Research and Development, Beerse, Belgium.

Authors

Aerssens J, Darling J, Fanning G, Fried MW, Johansson S, Talloen W, Tuefferd M

Studies

Virahep-C

Citation

Johansson S, Talloen W, Tuefferd M, Darling J, Fanning G, Fried MW, Aerssens J. High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity. Liver Int 2016 Mar;36(3):344-52. Epub 2015 Sep 6.

Abstract

Sustained virological response (SVR) following peginterferon (pegIFN) and ribavirin (RBV) treatment in hepatitis C virus (HCV)-infected patients has been linked with the IL28B genotype and lower peripheral levels of the CXCR3-binding chemokine IP-10 (CXCL10). To further improve the understanding of these biomarkers we investigated plasma levels of the other CXCR3-binding chemokines and activity of the dipeptidyl peptidase IV (DPP4, CD26) protease, which cleaves IP-10, in relation to treatment response.